| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 36877 | Trends in Biotechnology | 2016 | 5 Pages |
Abstract
Genome editing, represented by CRISPR/Cas9, facilitates somatic and germline gene modifications in many species, including humans. However, one of key issues, off-target mutation deserves special consideration prior to clinical applications. We herein discuss the importance of risk information on genome editing for obtaining legitimate patient consent and social acceptance.
Related Topics
Physical Sciences and Engineering
Chemical Engineering
Bioengineering
Authors
Motoko Araki, Tetsuya Ishii,